OPINION: Nipah is back in Kerala — and this time, the world has no vaccine and no plan

OPINION: Nipah is back in Kerala — and this time, the world has no vaccine and no plan

Introduction: A virus the world keeps forgetting — until it can't

The sixth resurgence since 2018

In June 2026, health authorities in Kerala, southern India, confirmed the sixth outbreak of Nipah virus in the state since 2018. One confirmed case. 104 contacts under active monitoring. Intensive care units on alert. The same protocol, the same anxiety, the same uncomfortable question that surfaces every time this virus reappears: how long before our luck runs out? Nipah kills between 40 and 75 percent of those it infects depending on the strain. There is no approved vaccine. There is no proven antiviral treatment. What exists is an isolation protocol and the hope that the chains of transmission will be broken before they become a catastrophe.

The World Health Organization has classified Nipah as a priority pathogen — meaning it is on the short list of viruses most likely to trigger a global pandemic. Not because it spreads easily — it does not, at least not in its current form — but because its combination of high lethality, zoonotic origin, and the absence of medical countermeasures makes it uniquely dangerous if it were ever to acquire more efficient human-to-human transmission. Every outbreak in Kerala is, in the epidemiological vocabulary, a near miss. And near misses, by definition, do not always end well.

Kerala's paradox: model of response, prisoner of recurrence

Kerala is not a failing state when it comes to health. Quite the opposite. Its public health infrastructure is among the most robust in India — high literacy rates, a dense network of hospitals, and a health bureaucracy that has learned, from bitter experience, to respond quickly to Nipah outbreaks. The 2018 outbreak — the first in the state — killed 17 of 19 confirmed cases, including a nurse who died caring for her patients. It was traumatic. It left a mark. And it produced a response protocol that is today considered a model by the WHO and international health organizations.

But here is the paradox: Kerala's model response capacity is not a solution to the underlying problem. It is an adaptive response to a structural failure. The structural failure is this: eight years after the first Kerala outbreak, after six resurgences, after dozens of studies identifying fruit bats of the genus Pteropus as the primary reservoir, the world still has no vaccine, no approved treatment, and no systematic strategy for reducing human exposure to the reservoir. Kerala is excellent at managing crises. The international community is failing at preventing them.

The Nipah virus: what it is, how it kills, why it terrifies

A paramyxovirus with devastating clinical features

Nipah virus is a paramyxovirus of the genus Henipavirus, first identified in 1999 in Malaysia following an outbreak among pig farmers that killed 105 people and led to the culling of over a million pigs. Its clinical picture is particularly severe: the infection begins with flu-like symptoms — fever, headache, muscle pain — before potentially progressing to acute encephalitis, causing convulsions, altered consciousness and, in the most severe cases, coma and death within 24 to 48 hours. The case fatality rate varies between 40 and 75 percent, depending on the strain and the quality of care available.

What makes Nipah particularly worrying from a pandemic risk perspective is its genetic plasticity. RNA viruses mutate rapidly, and several studies have identified specific mutations that could theoretically increase the efficiency of human-to-human transmission. Currently, transmission requires close contact with an infected person's bodily fluids — which limits natural spread but makes healthcare workers particularly vulnerable. The 2018 Kerala outbreak killed the nurse Lini Puthussery, who had cared for infected patients without knowing the nature of the disease. Her death became a symbol of the medical community's exposure to a poorly understood threat.

The fruit bat reservoir and deforestation dynamics

Fruit bats of the genus Pteropus — commonly known as flying foxes — are the natural reservoir of Nipah virus. They carry the virus without showing symptoms, excreting it through their urine, saliva, and the partially consumed fruits they drop. Human contamination occurs through consumption of these contaminated fruits — particularly date palm sap, harvested in Bangladesh and West Bengal through processes that expose it to bat excretions — or through direct contact with infected animals or their secretions.

The accelerating deforestation of bat habitats in South Asia is pushing these animals closer to human settlements and agricultural areas, multiplying the opportunities for spillover. This dynamic is not specific to Nipah — it is the common thread linking the emergence of most zoonotic diseases of the last thirty years: SARS, MERS, Ebola, COVID-19. The destruction of natural habitats creates the conditions for viral traffic between animal populations and humans. Every deforested hectare in Kerala, in Bangladesh, in Indonesia is a potential bridge between animal viruses and human populations. We are building these bridges ourselves, methodically, at an accelerating pace.

The 2026 outbreak: facts, response, and the 104 under surveillance

The confirmed case and initial response

The 2026 outbreak began with a single confirmed case — a patient in Kerala who tested positive for Nipah virus in June 2026. The Kerala health authorities, drawing on the protocols developed since 2018, immediately activated their emergency response plan: identification and isolation of all close contacts, enhanced surveillance in health facilities, public information dissemination, and direct communication with the WHO. The 104 contacts placed under active monitoring represent the known risk perimeter — people who had direct or indirect contact with the confirmed patient before isolation.

The quality of this initial response deserves to be acknowledged. In many parts of the world, a single Nipah case would generate significant delays in identification, notification, and contact tracing. Kerala has built a system that minimizes these delays. The WHO was notified rapidly. International protocols were activated. This speed is not automatic — it is the product of years of institutional learning, investment in public health infrastructure, and a culture of transparency that is not universal among regional health authorities. The 2026 response, in its early stages, is textbook. The question is whether it will be enough.

The 104 contacts: a map of risk

The 104 contacts under active monitoring are not all equal in terms of risk. Epidemiologists distinguish between high-risk contacts — people who had direct exposure to bodily fluids of the confirmed case — and low-risk contacts — people who were in the same environment but had no direct exposure. The distribution of these 104 people across the two categories will determine the true scale of the threat. If the majority are low-risk, the situation is manageable. If a significant proportion are high-risk, the probability of secondary cases increases substantially.

The 21-day incubation period of Nipah means that this active monitoring phase is not a formality. Every person under surveillance must be followed daily, their temperature monitored, their symptoms reported immediately. This requires significant human and logistical resources — resources that Kerala has, but that many of the regions where Nipah could next emerge do not. The 2026 outbreak is, for the moment, a test of a known system. The next outbreak, elsewhere, could be a test of systems that do not yet exist.

The absence of a vaccine: a conscious collective choice

CEPI and the chronic underfunding of neglected pathogens

The Coalition for Epidemic Preparedness Innovations (CEPI) was created in 2017 — after the West African Ebola crisis — with precisely the mission of funding the development of vaccines against priority pathogens, including Nipah. Several vaccine candidates are in various stages of development. A Nipah vaccine based on the Hendra virus envelope glycoprotein — developed by Vaccitech and others — has shown promising results in Phase I trials. But promising Phase I results and a licensed, deployable vaccine are separated by a chasm of funding, clinical trials, and regulatory processes that takes years and costs hundreds of millions of dollars.

Nipah suffers from the classic paradox of neglected diseases: it is too rare, in its current form, to attract the pharmaceutical investment that a market logic would justify, but potentially catastrophic enough to warrant a public investment that governments consistently fail to provide. CEPI has attempted to bridge this gap, but its resources — a few hundred million dollars across all its programs — are inadequate relative to the breadth of threats it is supposed to address. After six outbreaks in eight years in a single Indian state, the absence of an approved vaccine is not a scientific failure. It is a political choice — a revealed preference for reactive management over proactive prevention.

The COVID-19 lesson not fully learned

The COVID-19 pandemic demonstrated — in the most painful possible way — that investing in pandemic preparedness before a crisis is vastly more cost-effective than responding to one after it hits. The economic and human cost of COVID-19 dwarfs by orders of magnitude what would have been required to build robust global preparedness infrastructure, including vaccine platforms for priority pathogens. This lesson was loudly proclaimed in the months following the 2020 shock. The Pandemic Fund was created under the G20. Commitments were made. Declarations were signed.

By 2026, many of these commitments have not been followed through with the sustained funding and political attention they required. The urgency of COVID-19 created a temporary window of political will for pandemic preparedness — a window that has largely closed as the acute memory of the pandemic fades and other crises compete for attention. Nipah is still without an approved vaccine. The Pandemic Treaty negotiations at the WHO have been slow and contentious. And in Kerala, health workers are once again isolating contacts, taking temperatures, and hoping the chain breaks before it doesn't.

The WHO alert and international coordination

Disease Outbreak News and global notification mechanisms

The WHO publishes Disease Outbreak News (DON) for events meeting established notification thresholds under the International Health Regulations (IHR 2005). The 2026 Kerala Nipah outbreak triggered such a notification, making it part of the global health surveillance record. This mechanism — often invisible to the general public — is in fact a critical piece of global health architecture: it ensures that health authorities worldwide are informed of priority events, can calibrate their own surveillance accordingly, and can coordinate support if needed.

The WHO notification system is, in theory, the foundation of global health solidarity. In practice, its effectiveness depends on member states' willingness to notify rapidly and transparently — a willingness that is not always present when political and economic costs of disclosure are perceived as high. India's notifications on Nipah have generally been prompt and transparent, which partially explains why Kerala's response is regarded as a model. Transparency enables coordination. Coordination enables containment. The incentive structure of the IHR should reward this transparency more explicitly than it currently does.

Regional preparedness and the South Asian Nipah corridor

The Nipah threat is not limited to Kerala. Bangladesh has experienced repeated outbreaks since 2001, with a distinct transmission pattern — primarily through consumption of raw date palm sap contaminated with bat secretions. West Bengal, sharing borders with Bangladesh and neighboring Kerala, has seen cases. The epidemiological geography of Nipah defines a South Asian corridor of risk that spans multiple countries, languages, health systems, and political jurisdictions.

Coordinated regional preparedness — shared surveillance systems, joint outbreak response protocols, harmonized case definitions, coordinated stockpiling of personal protective equipment and diagnostics — is essential for managing a pathogen that does not respect national boundaries. The South-East Asia Regional Office of the WHO (SEARO) has made progress on regional coordination, but resources and political commitment vary considerably across member states. Building a regional Nipah response architecture that is robust enough to handle a larger outbreak — one that crosses state or national borders simultaneously — remains an unfinished priority.

The healthcare workers in the line of fire

The martyrdom of Lini Puthussery and its lasting lessons

The name Lini Puthussery should be known beyond Kerala. She was the nurse who died in 2018 after caring for a Nipah-infected patient without knowing the diagnosis, without adequate protection, and without any treatment to offer her patients or herself. Her death — and the deaths of others in that first outbreak — triggered the institutional response that made Kerala's subsequent outbreak management so much more effective. She paid, with her life, for lessons that should have been learned before she ever had to face that virus.

By 2026, Kerala's healthcare workers have personal protective equipment protocols, training, and institutional memory that Lini did not have. But the underlying vulnerability remains: they are treating a disease for which there is no treatment, using protective measures that reduce but do not eliminate risk, in facilities that can be overwhelmed if transmission accelerates. The 2026 response is better than 2018. It should not have taken a martyr to make it so — and the fact that an approved vaccine still does not exist means that healthcare workers in 2026 remain exposed to a risk that international investment could have substantially reduced.

Mental health costs and the recurring burden on health systems

Each Nipah outbreak in Kerala imposes costs that go beyond the direct clinical management of cases. The mental health burden on healthcare workers — anxiety, vigilance fatigue, the psychological weight of managing a deadly disease with limited tools — is significant and cumulative. Health workers who have lived through three, four, five outbreaks carry a form of chronic stress that standard occupational health systems are not well equipped to address. Research on the psychological impacts on health workers in Kerala's repeated Nipah outbreaks is limited — itself a gap in global understanding of the full costs of recurring outbreak management.

The economic costs extend to the broader Kerala economy. Tourism, agricultural markets, and daily commerce are disrupted during outbreak periods as precautionary measures and public anxiety reduce movement. The 2018 outbreak is estimated to have cost the state hundreds of millions of rupees in economic activity forgone. Each subsequent outbreak repeats this disruption at some scale. The aggregate economic cost of the absence of a vaccine — across all six outbreaks since 2018 — is a number that should be calculated explicitly and placed on the table in international discussions about pandemic preparedness funding. It would make a compelling case for investment.

The politics of pandemic preparedness: where funding goes and why

The hierarchy of pharmaceutical investment

The global pharmaceutical industry invests in vaccine development according to a logic that is primarily commercial. Diseases with large, wealthy markets attract investment. Diseases that primarily affect populations in low- and middle-income countries, that produce outbreak clusters rather than continuous mass demand, and that require ultra-cold chain or complex deployment logistics — these diseases attract much less private investment. Nipah checks all the boxes for pharmaceutical neglect: it is currently concentrated in South Asia, it is episodic rather than continuous, and its outbreak scale — a few dozen to a few hundred cases — does not produce the mass demand that justifies commercial vaccine development.

This market logic is not a moral condemnation of the pharmaceutical industry — it is a description of how market incentives work, and why market incentives alone are insufficient for pandemic preparedness. The argument for public investment in vaccines against pathogens like Nipah, Marburg, and Crimean-Congo hemorrhagic fever is not philanthropic. It is strategic: the cost of developing these vaccines in advance is a fraction of the cost of the global disruption they could cause if they were to acquire pandemic potential before countermeasures are ready. This is basic risk management mathematics. It is also, apparently, insufficiently compelling to produce the sustained political commitment required.

The international governance gap in pandemic preparedness funding

The Pandemic Fund, established under the G20 Indonesia Presidency in 2022, was created specifically to address the global health security financing gap. By 2026, its resources — approximately $2 billion in initial pledges — are widely considered insufficient relative to the scale of the preparedness challenge. The WHO estimates that the annual global investment gap in pandemic preparedness is on the order of $10 billion per year. The Pandemic Fund addresses a fraction of this gap, and its governance — with competing national interests represented on its board — has made prioritization contentious.

The broader Pandemic Treaty negotiations, ongoing since 2022, were intended to create a binding international framework for pandemic preparedness and response, including equitable access to vaccines and medical countermeasures. By mid-2026, negotiations remain difficult, with persistent disagreements between high-income and low-income countries over intellectual property rules, benefit-sharing, and the balance between national sovereignty and global obligations. The sixth Nipah outbreak in Kerala occurs in the middle of a world still debating the governance framework that should have been in place years ago.

The global risk calculus: from outbreak to pandemic potential

What would it take for Nipah to become a pandemic threat?

Nipah in its current form is not a pandemic pathogen. Its basic reproduction number (R0) is estimated to be below 1 in most outbreaks — meaning that, on average, each infected person transmits to fewer than one other person. Chains of transmission tend to be short and self-limiting when contact and isolation protocols are implemented promptly. This is why six outbreaks in Kerala have not produced a pandemic — the epidemiology, in its current form, works against wide propagation.

But the concern — and the reason Nipah sits on the WHO priority list — is the possibility of adaptive evolution. Specific mutations in the attachment glycoprotein or the fusion protein of Nipah could theoretically increase airborne transmission efficiency without necessarily reducing virulence. This is not an inevitable trajectory — most viruses do not acquire pandemic potential through mutation. But with a case fatality rate between 40 and 75 percent, even a modest increase in transmissibility would produce consequences that are difficult to overstate. A Nipah strain with COVID-19 transmission dynamics and Nipah's current lethality would be among the most catastrophic pathogens in modern history.

The surveillance imperative: seeing threats before they become crises

Detecting the evolution of Nipah toward enhanced transmissibility — if it were to occur — requires a global genomic surveillance system of a quality that does not yet uniformly exist. COVID-19 produced a major investment in genomic surveillance capabilities, particularly in high-income countries. But the regions where Nipah circulates — South Asia, parts of Southeast Asia — are precisely the regions where genomic surveillance capacity remains uneven. Detecting a dangerous mutation early requires sequencing capacity, bioinformatics expertise, and international data-sharing protocols that are still being built.

The Global Initiative on Sharing All Influenza Data (GISAID), extended beyond influenza during COVID-19, provides a partial framework for sharing pathogen genomic data. But systematic Nipah surveillance — continuous, not just outbreak-triggered — requires sustained investment in bat population monitoring, environmental sampling, and human-animal interface surveillance that goes beyond what current programs provide. The science of anticipatory surveillance is advancing. Its deployment, at the scale and in the locations where it is most needed, lags behind.

India's response and the lessons for global health architecture

A federal health system under pressure

India's constitutional structure places public health primarily under state jurisdiction — meaning that Kerala's exceptional outbreak management capacity is not automatically replicated in other Indian states. A Nipah outbreak in Uttar Pradesh or Bihar — with less robust public health infrastructure — would present a significantly different challenge. The country's National Centre for Disease Control (NCDC) and the Indian Council of Medical Research (ICMR) provide central coordination, but the operational response remains primarily at the state level. This creates a preparedness landscape that is uneven within a single large country.

India's role in global pandemic preparedness is growing — it is the world's largest producer of vaccines, hosting manufacturers that supplied the majority of COVID-19 vaccines deployed in low- and middle-income countries. This manufacturing capacity is a genuine global asset. But the translation of manufacturing capacity into proactive vaccine development for priority pathogens requires investment signals — purchase commitments, guaranteed markets, advance market commitments — that the international community has been slow to establish for pathogens like Nipah. The capacity to respond is present. The incentives to develop the tools in advance are not.

The international community's debt to Kerala

Kerala has, over eight years and six outbreaks, absorbed the consequences of a global preparedness failure that is not of its making. It has developed response protocols, trained healthcare workers, built institutional memory, and contained outbreak after outbreak — at cost to its health system, its economy, and the wellbeing of its population. The international community has benefited from this containment without adequately compensating for it, either in the form of sustained research investment or in the form of funding for the vaccine development that would reduce the burden Kerala bears.

There is something deeply inequitable about this arrangement. The populations most exposed to Nipah — in Kerala, in Bangladesh, in West Bengal — are not the populations making the funding decisions that determine whether a vaccine gets developed. They bear the risk. Others hold the budgets. The WHO's priority pathogen list is, among other things, a moral claim on international resources. Translating that moral claim into actual funding for Nipah vaccine development is a matter of political will. That political will has been declared many times. It has not yet been fully exercised.

What must change: a concrete agenda for action

Accelerate Nipah vaccine development with public funding

The most urgent priority is straightforward: adequately fund the most advanced Nipah vaccine candidates through Phase II and Phase III clinical trials. Several candidates exist with promising Phase I data. The bottleneck is not scientific — it is financial. The cost of completing Nipah vaccine development is estimated in the hundreds of millions of dollars — a fraction of the economic damage produced by a single major outbreak, and a vanishingly small fraction of the cost of a Nipah pandemic. The CEPI framework is the right vehicle. It needs the funding to match its mandate. G7 and G20 governments should make Nipah vaccine completion a named priority in their pandemic preparedness commitments.

In parallel, an advance market commitment for a licensed Nipah vaccine — guaranteeing a minimum purchase price for a defined number of doses — would provide the commercial signal needed to attract pharmaceutical co-investment. The model was used for COVID-19 vaccines with considerable success. Applied to Nipah, it would dramatically accelerate the timeline to availability. This is not a utopian proposal. It is a policy tool with proven effectiveness, awaiting political decision.

Build systematic human-animal interface surveillance

A Nipah vaccine is a critical tool, but it is not the only lever. Systematic reduction of human exposure to the virus reservoir — through habitat protection, agricultural practice changes, and targeted public health communication in high-risk communities — can reduce spillover events. This requires sustained monitoring of bat populations in the Nipah corridor, including genomic surveillance to detect potential mutations toward enhanced transmissibility. It requires community engagement programs in the regions where human-bat contact is most frequent — particularly around the harvesting of date palm sap in Bangladesh and similar practices elsewhere.

The One Health approach — integrating human, animal, and environmental health surveillance — is the conceptual framework for this work. Its translation into funded, operational programs at the country level is uneven. Strengthening One Health surveillance in the Nipah corridor is a long-term investment that would reduce not only Nipah risk but also the risk of other zoonotic spillovers from the same reservoir. This is pandemic preparedness at its most efficient — addressing root causes rather than managing downstream consequences.

The media's role in outbreak management: between transparency and panic

How information quality shapes public response

The quality of public communication during a Nipah outbreak matters — both for effective containment and for avoiding the panic that can undermine response efforts. Premature or inaccurate reporting of Nipah cases has, in past outbreaks, led to flight from affected areas, overwhelming of health facilities by worried-well patients, and stigmatization of affected communities — all of which complicate containment. Kerala's health authorities have developed increasingly sophisticated public communication strategies over the course of six outbreaks: clear, factual messaging about transmission risk, regular updates on the status of contact monitoring, and consistent emphasis on the manageable nature of the current outbreak while acknowledging its seriousness.

The media ecosystem in which this communication occurs has changed dramatically since 2018. Social media amplification of fear — based on misunderstood statistics, historical comparisons to larger outbreaks, or deliberately sensationalized content — can generate panic that is disproportionate to the actual epidemiological situation. The 2026 outbreak has already produced a cycle of social media anxiety that has required active management by health authorities. This is now a structural feature of outbreak response — not a side issue, but a core communication challenge that requires resources, strategy, and speed that public health systems were not originally designed to provide.

International media attention and its perverse incentives

International media attention to Nipah outbreaks tends to be inversely proportional to the response quality. Precisely because Kerala's response is effective — the outbreak is identified quickly, contacts are traced promptly, the chain breaks before major secondary transmission — the story generates brief attention and then disappears. A poorly managed outbreak that spreads further would generate sustained coverage. This creates a perverse incentive structure in which success in containment generates less attention — and therefore less political pressure for the long-term investments that would make containment unnecessary.

This is not a media criticism — it is a structural feature of how news cycles work. It is also an argument for the kind of sustained expert advocacy and institutional pressure that can maintain political attention to pandemic preparedness between crises. CEPI, the WHO, and civil society organizations working on global health security perform this function, but their voice is often drowned out when no major outbreak is generating headlines. The sixth Nipah outbreak in Kerala is an opportunity to make that case again — and to insist that success at containment is not a reason for complacency, but a reason to act before the seventh.

The geopolitics of health: when pandemic risk meets strategic competition

Health security as a dimension of national power

The management of pandemic risk has become, since COVID-19, an explicit dimension of national security and geopolitical competition. Countries' ability to develop, produce, and deploy vaccines against emerging pathogens is now understood as a strategic capability — not just a public health capacity. This framing has generated new investment in domestic vaccine manufacturing in Europe, the United States, and major emerging economies. It has also complicated international cooperation: when pandemic preparedness is framed primarily as national security, the incentive to share data, tools, and resources with other countries is reduced.

For pathogens like Nipah — concentrated in South Asia, currently manageable at the local level, not yet a threat to high-income countries — this framing of health as national security is a double-edged sword. It has increased awareness of pandemic risk and generated some additional investment. But it has also produced a kind of preparedness nationalism that prioritizes domestic stockpiling over the global coordination that actually prevents pandemics from developing. A Nipah outbreak contained in Kerala is a global public good. It should be funded as one.

The equity imperative in pandemic preparedness

The distribution of pandemic preparedness investment and capacity across the globe is deeply inequitable. High-income countries — which will be most protected from the immediate consequences of a Nipah outbreak, given its current geographic concentration — hold the majority of global health security resources. The communities most at risk — in Kerala, Bangladesh, West Bengal — have built impressive response capacity under resource constraints, but they should not bear this burden alone. The equitable dimension of pandemic preparedness is not charity — it is rational risk management. A pathogen contained in a low-income setting is a pathogen that does not reach a high-income setting. The investment in global health security is an investment in domestic security, understood correctly.

The principle of international solidarity in health — enshrined in the WHO Constitution and reiterated in every major global health governance framework — needs to move from declaration to practice. For Nipah, this means: funded vaccine development through CEPI, advance purchase commitments that create production incentives, sustained support for regional surveillance capacity in South Asia, and a pandemic preparedness framework that explicitly recognizes the contribution of outbreak-bearing communities to global health security. Kerala is protecting the world. The world should help pay for it.

The 2026 outbreak in context: a symptom of a larger failure

Six outbreaks, one structural failure

The sixth Nipah outbreak in Kerala since 2018 is not, primarily, a story about a virus. It is a story about a system — a global health preparedness system that has recognized a clear and present danger, has the scientific tools to address it, and has consistently failed to mobilize the political and financial will to do so. The virus has not changed fundamentally. The bats have not gone away. The habitat destruction continues. And the international community is still having the same conversations about pandemic preparedness funding that it was having in 2018, in 2020, in 2022. The sixth outbreak is a symptom of a structural failure. The seventh — if it comes — will be too.

This is not a counsel of despair. It is a call for precision in diagnosis. The problem is not that we do not understand Nipah. It is not that we lack response protocols. It is not that Kerala's health workers are insufficiently dedicated. The problem is that the international funding and governance architecture for pandemic preparedness consistently underinvests in vaccines and surveillance for pathogens that have not yet become global emergencies. Changing this requires political will at the highest levels — the kind of will that COVID-19 temporarily generated and that has since partially dissipated. Rebuilding it is urgent. The clock is running.

The world is one mutation away from a different conversation

The epidemiological community has a phrase for situations like the current Nipah moment: a slow emergency. The threat is real, documented, quantifiable. The consequences of inaction are foreseeable. But the timeline is uncertain enough to allow delay — each contained outbreak reducing the urgency slightly, each quiet year without a major event feeding the temptation to treat preparedness as a lower priority. The Nipah situation in 2026 is a slow emergency. The conversation would change immediately if the current outbreak were to produce a chain of secondary transmissions, or if genomic sequencing of the circulating virus were to reveal a mutation toward enhanced airborne spread.

We should not wait for that conversation. We should have it now — on the basis of the risk data we already have, the preparedness gaps we already know, and the tools we could already be developing. A Nipah vaccine that is licensed and stockpiled before the seventh Kerala outbreak — or before the first outbreak somewhere with less robust response capacity — is worth more than a hundred emergency responses after the fact. This is not speculation. This is arithmetic. The world can afford the investment. What it appears to lack is the political will to make it.

The path forward: from managed crisis to genuine prevention

Concrete steps that can be taken now

Moving from repeated crisis management to genuine prevention of Nipah outbreaks requires actions that are specific, funded, and accountable. First, the G7 and G20 should name Nipah vaccine completion as a priority in their annual health security commitments, with specific funding tranches to CEPI tied to clinical trial milestones. Second, an advance market commitment for a licensed Nipah vaccine should be structured and announced — providing the manufacturing investment signal before the vaccine is needed in a crisis. Third, One Health surveillance in the South Asian Nipah corridor should be supported with sustained international funding, including genomic sequencing capacity and cross-border data sharing protocols.

Fourth, the Pandemic Treaty should include specific provisions for vaccines against WHO priority pathogens — including guaranteed access arrangements that ensure vaccine availability in the regions of highest outbreak risk as a first priority, not as an afterthought. Fifth, Kerala's response capacity and accumulated outbreak experience should be formally recognized and supported as a global health asset — through sustained partnership with the WHO SEARO, funding for documentation and sharing of protocols, and inclusion of Kerala's health officials in global pandemic preparedness governance processes. These are not revolutionary proposals. They are the logical next steps from the evidence in front of us.

The political economy of prevention

The fundamental obstacle to all of the above is political economy, not science. Prevention is invisible. A vaccine that stops an outbreak is a story that does not happen. A surveillance system that detects a mutation early is a threat that does not materialize. The political economy of democracies tends to reward visible action over invisible prevention — a ribbon-cutting for a new hospital generates political credit that a well-funded surveillance system does not. Overcoming this structural bias requires advocates — in civil society, in the scientific community, in the media — who are willing to make visible the costs of under-investment, the near-misses that statistics can capture, and the lives that prevention saves.

It also requires political leaders who are willing to spend political capital on long-term risk reduction rather than short-term crisis response. These leaders exist. They are often found in countries that have experienced the costs of pandemic failure — and Kerala has produced some of the most articulate advocates for global pandemic preparedness investment, partly because its population has lived with the consequences of inadequate global preparation for eight years. Their voice should be amplified. Their experience should inform global policy. And their repeated demonstration that effective response is possible — even without a vaccine — should be honored not with congratulations, but with the investment that makes their sacrifice unnecessary in the future.

Conclusion: the seventh outbreak cannot find us this unprepared

What six outbreaks should have taught us

The sixth Nipah outbreak in Kerala since 2018 has confirmed, once again, that the state's response capacity is exceptional. It has also confirmed, once again, that the international health community's preparedness for Nipah remains inadequate — no approved vaccine, incomplete surveillance architecture, insufficient pandemic treaty progress. If the current outbreak is contained, as previous ones have been, the correct response is not relief. It is determination — to use the window of relative calm to make the investments that will reduce the probability and severity of a seventh outbreak, or of a first outbreak somewhere with less robust response capacity.

The calculus is simple. The scientific pathway to a Nipah vaccine exists. The funding to travel that pathway is within the means of the international community. The political will is the limiting factor. Every outbreak that ends without a pandemic is borrowed time — time that should be used to close the gaps that the next outbreak could exploit. The world has been lucky with Nipah for eight years. Luck is not a strategy. The seventh outbreak deserves better than the same conversation we have had after each of the previous six. It deserves a vaccine.

A final word on urgency and responsibility

Urgency without specificity is useless. The international health community is very good at declaring urgency and very poor at sustaining the specific commitments that urgency requires. The concrete agenda for Nipah preparedness is not mysterious — it has been written in WHO reports, CEPI strategy documents, and academic journals for years. What is needed is not more analysis. What is needed is the decision by the governments of high-income countries, backed by the allocation of real resources, to treat the prevention of the next Nipah outbreak as a priority that is maintained through the periods of calm between crises — not only rediscovered when the next case is confirmed in Kerala. The seventh outbreak is coming. The question is only whether we will be better prepared than we were for the sixth.

By Maxime Marquette, columnist

Columnist's transparency note

Editorial positioning

This opinion piece expresses the columnist's views on global pandemic preparedness and the specific case of the 2026 Nipah virus outbreak in Kerala. It is based on published data from recognized international organizations including the WHO, CEPI, and peer-reviewed epidemiological literature. The interpretations and editorial positions are those of the author. The columnist has no financial interest in any pharmaceutical company or health organization mentioned in this piece.

Limitations of the analysis

The clinical and epidemiological data cited reflects the state of information available at the time of writing — the outbreak was ongoing and case counts and contact monitoring numbers were subject to change. The economic cost estimates cited are approximations from secondary sources. The vaccine development timeline estimates are based on current Phase I data and standard clinical trial projections — actual timelines could vary significantly based on scientific findings and funding availability.

Sources

Primary sources

World Health Organization — Disease Outbreak News: Nipah virus — India (Kerala), June 2026

CEPI — Nipah virus priority pathogen profile and vaccine development portfolio — 2026

Ministry of Health and Family Welfare, India — Nipah virus outbreak update, Kerala — June 2026

Secondary sources

Euromaidan Press — Nipah in Kerala: a test of global pandemic preparedness — June 2026

Foreign Policy — Nipah's sixth Kerala outbreak exposes chronic preparedness gaps — June 2026

The Guardian — WHO alert as Nipah resurfaces in Kerala for sixth time since 2018 — June 2026